StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Barclays Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)
March 9, 2026 4:01 PM
Barclays analyst Etzer Darout reiterated an Overweight rating and $224.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ)The analyst commented, "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
